title: Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate acute adverse events and efficacy of three-dimensional intensity- modulated radiotherapy (IMRT) combined with endocrine therapy for intermediate and advanced prostate cancer.
  
  
  METHODS
  Sixty-seven patients were treated with three-dimensional IMRT combined with maximum androgen blockade. The correlation between radiation-induced rectal injury and clinical factors was further analyzed.
  
  
  RESULTS
  After treatment, 21 patients had complete remission (CR), 37 had partial remission (PR), and nine had stable disease (SD), with an overall response rate of 86.5%. The follow-up period ranged from 12.5 to 99.6 months. Thirty-nine patients had a follow-up time of ≥ five years. In this group, three-year and five-year overall survival rates were 89% and 89.5%, respectively; three-year and five-year progression-free survival rates were 72% and 63%. In univariate analyses, gross tumor volume was found to be prognostic for survival (χ2 = 5.70, P = 0.037). Rates of leucopenia and anemia were 91.1% and 89.5%, respectively. Two patients developed acute liver injury, and a majority of patients developed acute radiation proctitis and cystitis, mainly grade 1/2. Tumor volume before treatment was the only prognostic factor influencing the severity of acute radiation proctitis (P < 0.05).
  
  
  CONCLUSIONS
  IMRT combined with endocrine therapy demonstrated promising efficacy and was well tolerated in patients with intermediate and advanced prostate cancer.
authors.affiliation: Department of Radiation Oncology, Fuzhou General Hospital of Nanjing Command, PLA, Fuzhou, China E-mail : chenghuihua@hotmail.com.
authors.forename: Hua-Chun
authors.initials: HC
authors.lastname: Luo
authors.forename: Hui-Hua
authors.initials: HH
authors.lastname: Cheng
authors.forename: Gui-Shan
authors.initials: GS
authors.lastname: Lin
authors.forename: Zhi-Chao
authors.initials: ZC
authors.lastname: Fu
authors.forename: Dong-Shi
authors.initials: DS
authors.lastname: Li
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects; D000813:Anilides / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D059248:Chemoradiotherapy / Q000009:adverse effects*; D003556:Cystitis; D005500:Follow-Up Studies; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009570:Nitriles / Q000009:adverse effects*; D011349:Proctitis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011832:Radiation Injuries / Q000175:diagnosis / Q000209:etiology*; D061089:Radiotherapy, Image-Guided / Q000009:adverse effects; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*; D015996:Survival Rate; D014105:Tosyl Compounds / Q000009:adverse effects*
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D017273:Goserelin; C053541:bicalutamide